DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)

3 Months Ended

Sep. 30, 2024

	Initial Valuations (on new derivative instruments entered into during the three months ended September 30, 2024)		September 30, 2024
Volatility		290-316%		282	%
Expected Remaining Term (in years)		0.50		0.01 - 0.47
Risk Free Interest Rate		4.43-4.88%		4.65-5.53	%
Expected dividend yield		None		None

	Balance at September 30, 2024		Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
			(Level 1)		(Level 2)		(Level 3)
Embedded conversion option liabilities	$	134,234	$	—	$	—	$	134,234
Total	$	134,234	$	—	$	—	$	134,234

PROPANC BIOPHARMA, INC. AND SUBSIDIARY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2024

(Unaudited)

	Balance at June 30, 2024		Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
			(Level 1)		(Level 2)		(Level 3)
Embedded conversion option liabilities	$	133,886	$	—	$	—	$	133,886
Total	$	133,886	$	—	$	—	$	133,886

The following is a roll forward for the three months ended September 30, 2024 of the fair value liability of price adjustable derivative instruments:

	Fair Value of
	Liability for
	Derivative
	Instruments
Balance at June 30, 2024	$	133,886
Initial fair value of embedded conversion option derivative liability recorded as debt discount		60,000
Initial fair value of embedded conversion option derivative liability recorded as derivative expense		27,182
Reduction of derivative liability upon debt conversion		(34,047	)
Change in fair value included in statements of operations		(52,787	)
Balance at September 30, 2024	$	134,234